Dr. Jacqueline Lui, President of Eagle IP Limited, gave a talk titled “Patent Portfolio Management, A Practical Approach” at the BIP Asia 2016.
我們過去活動
Recommended Insights
NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)
2025年9月4日In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]
閱讀更多 >
China Proposes New Examination Guidelines for Utility Models
2022年11月24日The Utility Model (UM) in China has always been a popular choice for patent filing due to its relatively low cost and speed of prosecution. The UM prosecution only includes a preliminary examination, which is essentially a mini (stripped down) version of an invention application’s substantive examination.1 With the simplified examination process, UMs are typically […]
閱讀更多 >
China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021
2020年4月23日China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]
閱讀更多 >
What Kind of Damage Awards Can You Get in China?
2022年6月16日Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]
閱讀更多 >